

09/202047  
300 Rec'd PCT/PTO 07 DEC 1998

20-4491P

ATTACH  
TO  
#5

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT: Kyogo ITOH et al.

APPLICATION NO.: New

GROUP:

FILED: December 7, 1998

EXAMINER:

FOR: TUMOR ANTIGEN PROTEINS, GENES THEREFOR, AND TUMOR ANTIGEN  
PEPTIDES

INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION CONCURRENT WITH THE  
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents  
Washington, D.C. 20231

December 7, 1998

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

— Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

X This application is a National Phase of a PCT application. Copies of the cited documents should be forwarded from the International Search Authority.

III. CONCISE EXPLANATION OF THE RELEVANCE  
(check at least one box)

- a. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**  
A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:  
The relevancy of JP 55-128847 can be determined from a review of the English Abstract attached thereto.
- b. ☐ **DOCUMENTS IN THE ENGLISH LANGUAGE**  
All of the patents, publications or other information are in the English language. No statement of relevancy is required.
- c. ☒ **ENGLISH LANGUAGE SEARCH REPORT**  
An English language version of the search report or action which indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).
- d. ☐ **OTHER**  
The following additional information is provided for the Examiner's consideration.

FEEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.


If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 CFR §1.16 or under §1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By

 #32,801  
GERALD M. MURPHY JR.  
Reg. No. 28,977  
P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Enclosures:   X   PTO-1449  
\_\_\_\_\_ Documents  
\_\_\_\_\_ Foreign Search Report  
\_\_\_\_\_ Fee  
\_\_\_\_\_ Other:

Rev. 11/6/98  
J:\IDSNEWAP.DOC